Skip to main content

Advertisement

Table 1 Baseline characteristics of patient cohort

From: German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients

Characteristics Group A: HCV/HIV co-infected patients Group B: HCV mono-infected patients p-values
Patients, n 88 84 0.666
Age (y), mean (min./max.) 45 (26/64) 45 (20/72) 0.763
Sex, male/female (%) 66/22 (75/25) 52/32 (61/38) 0.092
Genotype, n (%)    
 1 37/88 (42) 49/84 (58) 0.033
 2 3/88 (3) 9/84 (10) 0.060
 3 25/88 (28) 15/84 (17) 0.102
 4 2/88 (2) 5/84 (5) 0.222
Unknwon 21/88 (23) 6/84 (7) 0.003
Liver biopsy, n (%) 17/88 (19) 36/84 (42) 0.001
 Fibrosis F3 – F4, n (%) 6/17 (35) 10/36 (27) 0.251
HCV RNA in IU/ml, mean 4 714 165 3 453 862 0.487
(min./max.) (3/9 × 107) (3/3 × 107)  
HCV RNA > 800 000, n (%) 66/88 (75) 32/84 (38) 0.001
HCV RNA < 800 000, n (%) 22/88 (25) 52/84 (61) 0.001
Alanine transaminase in U/l, mean (min./max.) 78 (3/526) 105 (15/610) 0.098
Start of heptitis C therapy, n (%) 36 (40) 52 (61) 0.006
Liver biopsy, n (%) 10 (27) 27 (51) 0.024
 (Fibrosis F3 – F4, n (%) 5 (13) 8 (29) 0.846
HCV RNA in IU/ml, mean 4 799 700 3 222 000 0.530
(min./max.) (800/9 × 107) (3/2 × 107)  
HCV RNA > 800 000, n (%) 12 (33) 21 (40) 0.502
HCV RNA < 800 000, n (%) 24 (66) 31 (59) 0.502
Alanine transaminase in U/l, mean (min./max.) 94 (29/526) 120 (18/610) 0.321
Duration of therapy in weeks, mean (min./max.) 33 (1/152) 36 (10/128) 0.496
Ribavirin (weight adapted) in mg/week, mean 5764,28 7567,2 0.027
Peg-Interferon-alfa 2a, n (%) 27/36 (75) 41/52 (78) 0.672
Peg-Interferon-alfa 2b, n (%) 0/36 (0) 3/52 (5) 0.143
Non-peg-Interferon, n (%) 3/36 (8) 0/52 (0) 0.034